ARTICLE SUMMARY:
As Hologic moves beyond its leading positions in diagnostics for women’s health into broader markets for in vitro diagnostics, it is armed with appealing technologies and an invigorated, new management team, but it also faces growing competitive and scientific pressures.
(E ditor’s Note: In this article, we’re taking a deep look at Hologic’s in vitro diagnostics division. An article examining Hologic’s overall corporate strategy and two other divisions, Breast Health and Surgical Solutions, ran in the July 27, 2016 issue of The MedTech Strategist.)
